アルツハイマー病と糖尿病に対する潜在的なマルチターゲットの治療薬として,パイポロン系シフ基質分子
Asif Ahmad1, Uzma Salar2, Musa Özil3
1Third World Center for Science and Technology, H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.
Future medicinal chemistry
|August 30, 2025
まとめ
新しいピペロナル由来シフ基は,糖尿病とアルツハイマー病の酵素に対する二重作用阻害を示しています. これらの化合物は,両方の状態のための新しい治療法を開発するための有望な戦略を提供します.
科学分野:
- 薬剤化学
- 神経科学
- 薬理学について
背景:
- 糖尿病 (DM) とアルツハイマー病 (AD) の併発は,多機能治療薬の開発を必要とする.
- パイポロン製シフ基は,DMとADの両方に関与する酵素を標的とする可能性について調査されています.
研究 の 目的:
- 新しいピペロナル由来シフ基導体を合成し,特徴づけること.
- DM (α-アミラーゼとα-グルコシダゼ) とAD (アセチルコリネステラーゼとブチリルコリネステラーゼ) の主要な酵素に対するこれらの誘導体の抑制力を評価する.
- 合成された化合物の抗酸化特性を評価するために
主な方法:
- ピペロナル由来シフ基導体の合成と構造的特徴付け
- α-アミラーゼ,α-グルコシダゼ,アセチルコリネステラーゼ,ブチリルコリネステラーゼに対する in vitro 酵素阻害試験
- 運動分析と分子ドッキング研究
- 抗酸化作用の評価
主要な成果:
- 化合物7と17は,α-グルコシダースとα-アミラーゼに対する強力な阻害を示し,標準薬であるアカルボースを上回った.
- 化合物7と9はアセチルコレネステラスとブチリコレネステラスに対する有意な抑制効果を示し,ドネペジル塩化物の有効性を上回った.
- 合成された誘導体はまた,顕著な抗酸化能力を示した.
結論:
- いくつかのピペロナル由来シフ塩基誘導体は,糖尿病とアルツハイマー病の両方に関連する標的に対して有望な二重作用の抑制効果を示しています.
- これらの化合物は,併発性DMとADの管理のための新しい治療薬の開発の潜在的な主要候補である.
- これらのヒット候補のさらなる開発は正当化されています.
さらに関連する動画
06:17A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
Published on: May 22, 2018
12.0K
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.1K
関連する概念動画
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
02:30siRNA - Small Interfering RNAs
17.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.0K
01:26Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
01:15G Protein-coupled Receptors
13.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.3K